Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, but getting the editing ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

The Scottish Medicines Consortium (SMC) has accepted exagamglogene autotemcel (Casgevy, Vertex Pharmaceuticals) for use within NHS Scotland to treat sickle cell disease (SCD) in patients aged 12 years ...

A robust and quantitative map links chromatin modification and gene expression of cells during zebrafish embryogenesis.

DNA does not float freely in the cell. Instead, it is wrapped around histone proteins to form structures called nucleosomes.

Researchers at EPFL have created CenSpark, a fluorescent probe that selectively labels centrioles and cilia in living cells across species. The tool enables unprecedented live imaging without genetic ...